SEC Form 4 · accession 0001104659-18-004329
Amphastar Pharmaceuticals, Inc. · AMPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason B. Shandell
Officer — President and General Counsel · Director
Period of report
Jan 25, 2018
Accepted (ET)
Jan 26, 2018 · 6:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001297184
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jan 25, 2018 | S | 8,661 | $19.2613 | D | 226,914 | D | |
| Common StockF4 | Jan 26, 2018 | S | 9,966 | $19.559 | D | 216,948 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2017.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.17 to $19.40 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.
- F3Includes 82 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on November 30, 2017.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.42 to $19.84, inclusive.